

SPINE SAFETY NOTICE:

Updated Prescribing Information for [Cipro I.V. \(ciprofloxacin\) for Intravenous Infusion](#), [Cipro \(ciprofloxacin hydrochloride\) Tablets](#), [Cipro \(ciprofloxacin\) Oral Suspension](#), [Cipro XR \(ciprofloxacin extended-release tablets\)](#)

According to MedWatch, the FDA Safety Information and Adverse Event Reporting Program, there have been revisions to the CONTRAINDICATIONS and WARNINGS sections of the prescribing information for Cipro IV, Cipro Tablets, Cipro Oral Suspension and Cipro XR. The revised CONTRAINDICATIONS and WARNINGS labeling indicates Ciprofloxacin is contraindicated in persons with a history of hypersensitivity to ciprofloxacin, any member of the quinolone class of antimicrobial agents, or any of the product components. Concomitant administration with tizanidine is contraindicated. Ciprofloxacin is an inhibitor of the hepatic CYP1A2 enzyme pathway. Coadministration of ciprofloxacin and other drugs primarily metabolized by CYP1A2 (e.g. theophylline, methylxanthines, tizanidine) results in increased plasma concentrations of the coadministered drug and could lead to clinically significant pharmacodynamic side effects of the coadministered drug.

The MedWatch 2005 Safety Summary (detailed view) is available at <http://www.fda.gov/medwatch/SAFETY/2005/nov05.htm>.

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety-related notices that may be useful to our members. Information from these notices is also archived on the NASS Web site at http://www.spine.org/spine_safety_notices.cfm. This information is provided as a service for information and education only.